Recent Company News

• 04:33 PM ET Aug 18, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:44 AM ET Aug 18, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 01:04 PM ET Aug 15, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 17-Aug

• 10:50 AM ET Aug 15, 2025
  

  Pfizer announces phase 3 THRIVE-131 study of inclacumab in sickle cell disease did not meet primary endpoint (pre-open) ($25.17, +0.05)

• 09:16 AM ET Aug 08, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:21 AM ET Aug 08, 2025
  

  StreetAccount Summary - US Pre-market trading

• 03:52 AM ET Aug 08, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 11:15 AM ET Aug 07, 2025
  

  Genmab reports Q2 net income $336M vs FactSet $261.4M [13 est, $202-308.2M] (DKK 1446.50, 0.00)

• 10:34 AM ET Aug 07, 2025
  

  Genmab A/S r positive results of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in combination with rituximab and lenalidomide (R2) versus R2 alone for the treatment of adult patients with R/R FL (DKK 1419.50, +42.50)

• 01:28 PM ET Aug 01, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 3-Aug